You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
昭衍新藥(06127.HK)年度實現純利3.13億元 同比增長66.6%
格隆匯 03-29 23:43

格隆匯 3 月 29日丨昭衍新藥(06127.HK)發佈截至2020年12月31日止年度的年度業績公吿,報吿期內,集團的非臨牀研究服務產生的收益佔集團總收益的絕大部分。集團該年度的收益為人民幣10.759億元,同比增加68.3%。有關增加主要是由於業務拓展(包括於2019年12月收購Biomere)。公司權益股東應占年內溢利人民幣3.13億元,同比增長66.6%。基本每股盈利人民幣1.39元。

截至2020年12月31日止年度,毛利及毛利率分別為人民幣5.506億元及51.2%,相對上年度則分別為人民幣3.288億元及51.4%。毛利增加主要由非臨牀研究服務的毛利增加所驅動,報吿期內,其佔集團總收益的絕大部分。截至2020年12月31日止年度,毛利率輕微下滑,主要是由於為支持非臨牀研究服務而採購的非人靈長類實驗模型的成本上漲及收購Biomere(該公司主要提供非GLP服務,與集團提供的GLP服務相比,利潤率相對較低)。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account